Moreover, CRC-113 gene signature further stratified the patients with KRAS and BRAF WTs, and p53 M. Therefore, we argue that CRC-113 gene signature can overcome limitations of the conventional molecular markers via further stratification in CRC predicting prognosis. This evidence concerns the gene KRAS and colorectal carcinoma.